Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced enhanced chemistry of its Invitae Personalized Cancer Monitoring™ platform...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2023 financial results on Wednesday,...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced findings from the largest study to date on uncertain results from...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of veteran healthcare leader David Sholehvar, M.D., as...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced results of its collaborative study on universal hereditary cancer genetic...
Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, are showcasing their work next week at the National Society of Genetic...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced it gained FDA market authorization for its Common Hereditary Cancers Panel. ...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it received a notice from the New York Stock Exchange (the "NYSE") on...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it has appointed Robert (Rob) Guigley as its chief commercial officer, ...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced findings from its PROCLAIM trial, published in European Urology Oncology,...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Robert Dickey has been named its interim chief financial officer...
– Reported revenue of $120.5 million, a 12% year-over-year decrease due to exited businesses and geographies; pro forma revenue up slightly...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2023 financial results on Tuesday,...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Ken Knight, president and chief executive officer, will present at the ...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced nine studies to be presented at the 2023 American Society of Clinical...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Chief Financial Officer (CFO) Yafei (Roxi) Wen is resigning to pursue...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it intends to appeal the verdict delivered by a jury at the United...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2023 financial results on Tuesday,...
Invitae (NYSE: NVTA), a leading medical genetics company, today published its 2023 Environmental, Social and Governance (ESG) Report. This report...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced new research published in Nature describing the first use of the company's...
Invitae (NYSE: NVTA), a leading medical genetics company, and Deerfield Management Company, a healthcare investment firm, today announced a...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced its partnership with Epic, an industry-leading healthcare software company. ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.